Twist Bioscience posts preliminary Q1 2026 revenue

Twist Bioscience Corporation furnished a current report to share preliminary, unaudited revenue results for its first quarter of fiscal 2026, covering the period ended December 31, 2025.

Rhea-AI Filing Summary

Twist Bioscience Corporation furnished a current report to share preliminary, unaudited revenue results for its first quarter of fiscal 2026, covering the period ended December 31, 2025. The company announced these early revenue figures in a press release dated January 12, 2026, which is included as Exhibit 99.1. Twist notes that these revenue expectations are preliminary and may change after it completes its internal control, review, and audit procedures, so the final numbers in its quarterly financial statements could differ materially. The company also states that this information is being furnished, not filed, which limits how it is treated under securities law.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did Twist Bioscience (TWST) disclose in this 8-K?

Twist Bioscience furnished a press release announcing its preliminary, unaudited revenue results for the first quarter of fiscal 2026, for the period ended December 31, 2025.

Which period do Twist Bioscience’s preliminary results cover?

The preliminary, unaudited revenue results relate to Twist Bioscience’s first quarter of fiscal 2026, which ended on December 31, 2025.

How are the Twist Bioscience preliminary revenues characterized?

The company describes its first-quarter fiscal 2026 revenue expectations as preliminary and unaudited, and notes they may change after internal control, review, and audit procedures are completed.

Where can investors find the detailed preliminary revenue figures for Twist Bioscience?

The detailed preliminary revenue information is contained in the press release titled “Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue,” which is included as Exhibit 99.1.

Are Twist Bioscience’s preliminary revenue figures final?

No. Twist Bioscience states that the preliminary revenue amounts are subject to change and could differ materially from the figures that will appear in its unaudited condensed financial statements for the quarter.

Is the preliminary revenue information considered filed with the SEC?

The company specifies that the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 liability or automatically incorporated into Securities Act registration statements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/12/2026 - 08:13 AM Learn about SEC filing dates

FALSE000158128000015812802024-11-182024-11-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

January 12, 2026

Twist Bioscience Corporation

(Exact name of registrant as specified in its charter)

Delaware

001-38720

46-2058888

(State or other jurisdiction of incorporation)

(Commission File Number)

(I. R. S. Employer Identification No.)

681 Gateway Boulevard

South San Francisco, CA 94080

(Address of principal executive offices, including ZIP code)

(800) 719-0671

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

TWST

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02Results of Operations and Financial Condition.

On January 12, 2026, Twist Bioscience Corporation (the “Company”) issued a press release announcing its preliminary, unaudited revenue results for the first quarter ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The Company’s revenue expectations included in this Current Report on Form 8-K are preliminary and unaudited and are subject to change based on the completion of ongoing internal control, review and audit procedures. As a result, these amounts may differ materially from the amounts that will be reflected in the Company’s unaudited condensed financial statements for the fiscal quarter ended December 31, 2025. Accordingly, stockholders should not place undue reliance on this preliminary estimate.

The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.						Description
99.1						Press release dated January 12, 2026 titled “Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue”
104						Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 12, 2026			Twist Bioscience Corporation
			/s/ Judy Yan
			Judy Yan
			Assistant General Counsel and Assistant Secretary